Correction and Republication: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September

Correction and Republication: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

Published:2023-03-17 Issue:11 Volume:72 Page:292
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference3 articles.

1. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022.;Tenforde;MMWR Morb Mortal Wkly Rep,2022

2. International Committee of Medical Journal Editors (ICMJE). Corrections, retractions, republications and version control. Vancouver, Canada: International Committee of Medical Journal Editors (ICMJE); 2017. https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/corrections-and-version-control.html

3. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022.;Tenforde;MMWR Morb Mortal Wkly Rep,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England;The Lancet Regional Health - Europe;2023-12

2. Managing hospitalized patients with COVID-19;JAAPA;2023-10

3. Bolstering the Measurement of Racial Inequity of COVID-19 Vaccine Uptake;Vaccines;2023-04-21